tiprankstipranks
Advertisement
Advertisement

AU:ATX Stock Latest News

Amplia Halts New Recruitment in Pancreatic Cancer Trial After Chemo Toxicities
Company AnnouncementsAmplia Halts New Recruitment in Pancreatic Cancer Trial After Chemo Toxicities
4d ago
Amplia Halts AMPLICITY Recruitment, Shifts Focus to Less Toxic Pancreatic Cancer Regimens
PremiumCompany Announcements
Amplia Halts AMPLICITY Recruitment, Shifts Focus to Less Toxic Pancreatic Cancer Regimens
5d ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
16d ago
RADX
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
17d ago
Amplia posts unprecedented complete responses and survival gain in pancreatic cancer trial
PremiumCompany Announcements
Amplia posts unprecedented complete responses and survival gain in pancreatic cancer trial
20d ago
Amplia requests ASX trading halt ahead of key clinical trial data
PremiumCompany AnnouncementsAmplia requests ASX trading halt ahead of key clinical trial data
24d ago
Amplia Therapeutics Reappoints Experienced CFO to Support Biotech Growth
Premium
Company Announcements
Amplia Therapeutics Reappoints Experienced CFO to Support Biotech Growth
2M ago
Amplia Expands U.S. Footprint With New Sites for Pancreatic Cancer Trial
Premium
Company Announcements
Amplia Expands U.S. Footprint With New Sites for Pancreatic Cancer Trial
2M ago
Amplia Secures Phase 3-Ready Supply with First Large-Scale Narmafotinib Manufacture
PremiumCompany Announcements
Amplia Secures Phase 3-Ready Supply with First Large-Scale Narmafotinib Manufacture
3M ago
Amplia Showcases Promising Pancreatic Cancer Data for Narmafotinib at ASCO GI
PremiumCompany Announcements
Amplia Showcases Promising Pancreatic Cancer Data for Narmafotinib at ASCO GI
3M ago
Amplia Deepens Next & Bio Collaboration to Test Narmafotinib–kRAS Combo in Pancreatic Cancer
PremiumCompany Announcements
Amplia Deepens Next & Bio Collaboration to Test Narmafotinib–kRAS Combo in Pancreatic Cancer
4M ago
Amplia Therapeutics Reports Positive ACCENT Trial Results for Pancreatic Cancer
PremiumCompany Announcements
Amplia Therapeutics Reports Positive ACCENT Trial Results for Pancreatic Cancer
4M ago
Amplia Therapeutics Reports Promising Trial Results for Pancreatic Cancer Drug
PremiumCompany AnnouncementsAmplia Therapeutics Reports Promising Trial Results for Pancreatic Cancer Drug
5M ago
Amplia Therapeutics Receives FDA Support for Pancreatic Cancer Trial
Premium
Company Announcements
Amplia Therapeutics Receives FDA Support for Pancreatic Cancer Trial
5M ago
Amplia Therapeutics Issues New Equity Securities
Premium
Company Announcements
Amplia Therapeutics Issues New Equity Securities
5M ago
Amplia Therapeutics Expands U.S. Market Presence with OTCQB Listing
PremiumCompany Announcements
Amplia Therapeutics Expands U.S. Market Presence with OTCQB Listing
5M ago
Amplia Therapeutics Advances Narmafotinib Trials with Promising Results
PremiumCompany Announcements
Amplia Therapeutics Advances Narmafotinib Trials with Promising Results
6M ago
Amplia Therapeutics Secures $3.77 Million R&D Tax Rebate to Boost Cancer Trials
PremiumCompany Announcements
Amplia Therapeutics Secures $3.77 Million R&D Tax Rebate to Boost Cancer Trials
6M ago
Amplia Therapeutics Expands U.S. Presence with New Investor Campaign
PremiumCompany Announcements
Amplia Therapeutics Expands U.S. Presence with New Investor Campaign
6M ago
Amplia Therapeutics Reports Positive Results in Pancreatic Cancer Trial
PremiumCompany AnnouncementsAmplia Therapeutics Reports Positive Results in Pancreatic Cancer Trial
6M ago
Amplia Therapeutics Announces Cessation of Securities
Premium
Company Announcements
Amplia Therapeutics Announces Cessation of Securities
6M ago
Amplia Therapeutics Secures Key US Patent for Cancer Drug Narmafotinib
Premium
Company Announcements
Amplia Therapeutics Secures Key US Patent for Cancer Drug Narmafotinib
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >